Gray markets.
Patient safety first.
Putting medical necessity, qualified clinical judgment and patient safety ahead of a product promise.
Know the substance.
Understand the evidence.
Consider the person.
Uncertain identity, quality or clinical context can introduce risk. Even an accurately identified substance may be inappropriate for a particular patient.
Clear Health Pass plans an approach built around assessment, consent, traceable supply and follow-up. It is a plan, not an available treatment or proof of benefit.
Explore the planned pathways↗FIRST
Five questions worth asking.
Explore each question. This is an educational guide, not a test of treatment eligibility.
What is actually in the product?
An online label or a research-use-only disclaimer does not establish the identity, suitability or lawful patient use of a substance. Know the exact product and its source.
AI supports the record.
People guide the care.
Technology should help clinicians see a clearer picture, while keeping the patient’s needs and clinical judgment central.
CHP’s measurement, coverage documentation and audit tools support the clinical record; they do not independently establish that a peptide is safe, effective or medically necessary.
Meet the people behind the platform↗Source: FDA safety context ↗.
Make room for better questions.
Explore the education hub or speak with the team about the planned program.
HEAL WELL. AGE WELL. LIVE LONGER.